1-(2-吡啶基)戊-1,4-二酮 | 64388-88-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(2-吡啶基)戊-1,4-二酮
• 英文名称: 1-(2-pyridyl)pentan-1,4-dione
• 英文别名: 1-(Pyridin-2-yl)pentane-1,4-dione；1-pyridin-2-ylpentane-1,4-dione
• CAS: 64388-88-1
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: WIXUHWZXLXGAKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  47
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-吡啶基)戊-1,4-二酮 在 劳森试剂 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 55.0h， 生成 1-methyl-2-(5-methyl-2-thienyl)pyridinium iodide
  参考文献：
  名称：

  扩展的杂环系统2.（2-呋喃基）吡啶，（2-噻吩基）吡啶，呋喃-吡啶和噻吩-吡啶低聚物的合成和表征

  摘要：

  Stetter程序已经过调整，可以生产简单的2-呋喃基和2-噻吩基吡啶及其相关的低聚物，这些寡聚物已通过13 C NMR光谱进行了表征。由2-呋喃基和2-噻吩基吡啶的共轭酸的pK a值推导出2-呋喃基和2-噻吩基环的σ值。

  DOI：

  10.1016/s0040-4020(97)00745-x
• 作为产物：
  描述：

  吡啶-2-甲醛 、 丁烯酮 在 3-苄基羟乙基甲基噻唑氯化锂 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 12.0h， 以66%的产率得到1-(2-吡啶基)戊-1,4-二酮
  参考文献：
  名称：

  扩展的杂环系统1.吡咯基吡啶，交替的吡咯：吡啶低聚物和聚合物的合成与表征，以及相关系统

  摘要：

  Stetter程序已经过调整，可以生产低聚和聚合的吡咯基吡啶，这些化合物已通过13 C NMR光谱进行了表征。2-（吡咯-2-基）吡啶对季铵化的较低活性允许2-，3-和4-（吡咯-2-基）吡啶的选择性N-烷基化。

  DOI：

  10.1016/0040-4020(96)00448-6

文献信息

• THERAPEUTIC AGENT FOR DIABETES
  申请人：Japan Tobacco Inc.

  公开号：EP0885869A1

  公开（公告）日：1998-12-23

  A therapeutic agent for diabetes, which comprises a compound of the formula [I] wherein Xis a group of the formula wherein R4 and R5 are the same or different and each is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, and R6 is a hydrogen atom or an amino-protecting group; R1 is an optionally substituted alkyl having 1 to 5 carbon atoms, an optionally substituted alkenyl having 2 to 6 carbon atoms and the like, R2 is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, R2' is a hydrogen atom, and R3 is an optionally substituted alkyl having 1 to 5 carbon atoms and the like, a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof. The compound of the present invention shows superior blood sugar decreasing action on the state of hyperglycemia, but does not affect the blood sugar when it is in the normal range or in the hypoglycemic state, which means that it is free of serious side effects such as hypoglycemia. Therefore, the compound of the present invention is useful as a therapeutic drug for diabetes and also useful as a preventive of the chronic complications of diabetes.

  用于治疗糖尿病的疗法剂，包括公式[I]的化合物 其中 X是公式的组 其中R4和R5相同或不同，每个都是氢原子，可选地取代的具有1至5个碳原子的烷基等等，R6是氢原子或氨基保护基团；R1是具有1至5个碳原子的可选取代烷基，具有2至6个碳原子的可选取代烯基等等，R2是氢原子，具有1至5个碳原子的可选取代烷基等等，R2'是氢原子，R3是具有1至5个碳原子的可选取代烷基等等，其前药，药用可接受盐，水合物和溶剂化物。 本发明的化合物在血糖升高状态下表现出优越的降血糖作用，但在正常范围或低血糖状态下不影响血糖，这意味着它没有低血糖等严重副作用。因此，本发明的化合物作为治疗糖尿病的药物很有用，也用作预防糖尿病慢性并发症。
• CRTH2 MODULATORS
  申请人：MERMERIAN Ara

  公开号：US20110150834A1

  公开（公告）日：2011-06-23

  Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed. The compounds fall within a genus described by formula I:

  CRTH2的调节剂，特别是CRTH2的拮抗剂，可用于治疗各种疾病，包括哮喘和呼吸系统疾病。这些化合物属于由公式I描述的一类物质。
• Extended heterocyclic systems 1. The synthesis and characterisation of pyrrolylpyridines, alternating pyrrole: Pyridine oligomers and polymers, and related systems
  作者：R. Alan Jones、Marielena Karatza、Tevita N. Voro、Pervin U. Civeir、Annete Franck、Orhan Ozturk、John P. Seaman、Alexander P. Whitmore、David J. Williamson

  DOI：10.1016/0040-4020(96)00448-6

  日期：1996.6

  The Stetter procedure has been adapted to produce oligomeric and polymeric pyrrolylpyridines, which have been characterised by 13C NMR spectroscopy. The lower activity of 2-(pyrrol-2-yl)pyridines towards quaternisation permits selective N-alkylation of 2-, 3- and 4-(pyrrol-2-yl)pyridines.

  Stetter程序已经过调整，可以生产低聚和聚合的吡咯基吡啶，这些化合物已通过13 C NMR光谱进行了表征。2-（吡咯-2-基）吡啶对季铵化的较低活性允许2-，3-和4-（吡咯-2-基）吡啶的选择性N-烷基化。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME
  申请人：Shirai Junya

  公开号：US20110178060A1

  公开（公告）日：2011-07-21

  The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle; ring B is an aromatic ring optionally having substituent(s); ring D is an aromatic ring optionally having substituent(s); L is a group represented by the formula R 2 , R 3 , R 4a and R 4b are each independently a hydrogen atom, an optionally halogenated C 1-6 alkyl group or an optionally halogenated C 3-6 cycloalkyl group, or R 2 and R 3 are optionally bonded via an alkylene chain or an alkenylene chain, or R 4a and R 4b are optionally bonded via an alkylene chain or an alkenylene chain; R 1 is a hydrogen atom or a substituent; m and n are each independently an integer of 0 to 5; m+n is an integer of 2 to 5; and is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and the like.

  本发明涉及一种化合物，其表示为式： 其中，环A是一种含氮杂环；环B是一种芳香环，可选地具有取代基；环D是一种芳香环，可选地具有取代基；L是一个代表式为R2、R3、R4a和R4b的基团，其中R2、R3、R4a和R4b各自独立地是氢原子、可选卤代的C1-6烷基或可选卤代的C3-6环烷基，或者R2和R3通过烷基链或烯基链可选地连接，或者R4a和R4b通过烷基链或烯基链可选地连接；R1是氢原子或取代基；m和n各自独立地为0到5的整数；m+n是2到5的整数；以及为单键或双键，或其盐；等等。该化合物具有优良的缩氨酸受体拮抗作用，并可用作预防或治疗各种疾病的药剂，如下尿路疾病、消化道疾病、中枢神经系统疾病等。
• CRTH2 modulators
  申请人：Mermerian Ara

  公开号：US08674115B2

  公开（公告）日：2014-03-18

  Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed. The compounds fall within a genus described by formula I:

  本发明揭示了CRTH2的调节剂，特别是CRTH2的拮抗剂，用于治疗各种疾病，包括哮喘和呼吸系统疾病。这些化合物属于由式子I描述的属类。